© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Riociguat stands out as one of those drugs built on both hope and meticulous science. Scientists started pursuing new therapies for pulmonary hypertension several decades ago because standard treatments left patients struggling. In the early 2000s, the search turned to the body’s natural mechanisms for relaxing blood vessels, zeroing in on the soluble guanylate cyclase (sGC) pathway. After a long trail of basic research and painstaking clinical work, Bayer brought riociguat to market in the early 2010s. This drug showed promise for two devastating conditions: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The journey to approval involved trials enrolling hundreds of participants, with regulatory bodies eventually recognizing riociguat’s unique mechanism and clinical benefits. It earned approval in the US, Europe, and several other countries, adding a new chapter to the story of cardiovascular therapeutics.
Riociguat broke ground because it stimulates sGC both in the presence and absence of nitric oxide, something earlier therapies couldn’t match. Doctors prescribe it orally, usually starting with a low dose and titrating up based on individual tolerance and blood pressure response. The tablet comes in strengths ranging from 0.5 mg to 2.5 mg, and pharmacologists will tell you it has decent oral bioavailability, with the body handling most of it through the liver before excreting the leftovers via urine and feces. Patients with kidney or liver issues need close monitoring because the medicine accumulates more easily. Despite its benefits, riociguat can cause side effects like headache, dizziness, and indigestion, and it poses serious risk to pregnancy.
Riociguat appears as a white to off-white powder with a molecular weight of 422.42 g/mol and the chemical formula C20H19FN8O2. It is slightly soluble in water and more readily dissolves in organic solvents like methanol and DMSO. Its melting point sits between 230–235°C. The molecule includes a pyrimidine core joined with several aromatic rings, fluorine, and guanidine groups, making it structurally dense and pharmacologically versatile. The powder has only faint odor, and pharmacists assess its purity using chromatographic and spectrophotometric techniques.
Manufacturers place strict standards on things such as assay purity (usually above 98%), maximum limits for residual solvents, and acceptable related compound levels. The labeled tablet contains an exact dose of riociguat, plus common excipients to stabilize the compound and ease ingestion. The information that comes with the product warns about interactions with nitrates and PDE5 inhibitors, both of which can cause dangerous drops in blood pressure if combined with riociguat. Labels clearly state pregnancy warnings and guidelines for dose titration, as well as details on handling, storage (keep below 25°C, protect from moisture), and expiration. Pharmacists and physicians rely on these labels to track adverse reactions and make safe prescribing decisions.
Chemists synthesize riociguat using steps that build its pyrimidine and benzyl moieties in precise order. Starting from basic aromatic chemicals, the pathway stitches together the core ring system through cyclization reactions. Various controlled conditions, temperature gradients, and purification steps shape the final molecule, usually with catalysts guiding each stage. After synthesis, several rounds of recrystallization or chromatography scrub away impurities. Finished batches pass through analytical testing, looking for identity, purity, and expected melting behavior. The whole process takes place under regulations designed to guarantee batch-to-batch consistency and minimize risks of contamination.
Riociguat’s chemical structure allows small changes that shift its pharmacologic profile. Research groups have tried substituting the fluorine or altering the guanidine groups to see if such changes help in treating other diseases or reducing side effects. Some of these analogs have improved water solubility or longer half-lives, but few have matched the original molecule’s balance of activity and safety. Attempts to create prodrugs failed to deliver meaningful clinical benefits. The main challenge lies in preserving binding to the sGC enzyme while tweaking parts of the molecule to ease formulation or slow breakdown in the body.
Riociguat goes by several names in pharmaceutical and scientific circles. Its trade name Adempas pops up most frequently in clinical settings. Chemists may refer to it as BAY 63-2521, and international chemical databases use identifiers like UNII: S064D5E8ZU and CAS number 625115-55-1. These aliases help clinicians, pharmacists, and researchers track the drug across borders and scientific literature. Other synonyms include the IUPAC name (2-((4,6-diamino-pyrimidin-2-yl)-N-(2-fluorobenzyl)-N-methylbenzamide) and registry codes assigned by regulatory agencies and chemical suppliers.
Strict handling protocols surround riociguat from factory to pharmacy. Workers need gloves, eye protection, and sometimes fume hoods during synthesis because fine powders can escape easily, creating potential risks if inhaled. Laboratories keep standard operating procedures on file, tailored to local laws and health system requirements. Spills demand quick cleanup with designated absorbents. Hospitals store finished tablets away from direct light and humidity, locking up stocks to prevent misuse. Pharmacists counsel patients about risks with other vasodilators and emphasize that pregnancy must be avoided. Manufacturing sites undergo regular inspections by regulators to verify compliance with quality assurance and safety rules.
Doctors prescribe riociguat mainly to adults with PAH or CTEPH, and both are rare but life-threatening diseases. CTEPH patients, especially those who can’t undergo surgery, often benefit the most. Treatment teams rely on riociguat when other therapies like prostanoids, endothelin receptor antagonists, or phosphodiesterase-5 inhibitors either don’t work or aren’t tolerated. There’s a strong call for proper risk assessment: not every person with high lung pressure fits the profile for this therapy, so specialist consultation makes sense. Insurance coverage can be a hurdle, slowing patient access, and broader education around these diseases is badly needed in primary care to speed up diagnosis and referrals.
Ongoing research around riociguat investigates new indications, combination strategies, and biomarkers that can help predict treatment response. Scientists run trials to see if the drug helps patients with other types of pulmonary hypertension, such as those linked to lung fibrosis or heart disease. Labs experiment with once-daily dosing regimens and other formulations. A few teams look at combining riociguat with other PAH drugs to boost effectiveness. Researchers in academia and industry both contribute to this pipeline, chasing better patient outcomes and improved drug safety. Translational scientists also probe the sGC pathway for opportunities beyond pulmonary medicine, such as in heart failure and fibrotic disorders.
Both animal studies and post-market surveillance flesh out riociguat’s toxicity profile. At standard doses, the drug rarely causes severe adverse events, yet overdose leads to significant hypotension and risk of fatal shock. Animal models reveal reproductive toxicity, making contraception essential for women of childbearing age. Liver and kidney dysfunction increase the drug’s concentration, so clinicians adjust dosing or avoid prescribing in such situations. No strong cancer risk has turned up in long-term studies, and in clinical settings, most side effects resolve with dose adjustment or supportive care. Multiple regulatory agencies keep safety data under frequent review, updating guidelines as new information surfaces.
In the coming years, researchers aim to broaden riociguat’s role in treating vascular diseases. Efforts focus on developing long-acting analogs or easier-to-take formulations. Biomarker-driven approaches may help doctors identify which patients stand to benefit most, cutting down on trial-and-error prescribing. Specialists see potential in deploying riociguat earlier in treatment for CTEPH, possibly halting disease before lasting damage occurs. Access remains a challenge: raising awareness among frontline providers, simplifying regulatory hurdles, and lowering drug costs all deserve prioritization. Finally, public and private investment in rare disease research helps keep innovative drugs like riociguat on the agenda, offering hope to patients and families facing daunting diagnoses.
Breathing shouldn’t feel like a full-time job. Pulmonary hypertension turns every breath into a struggle. People living with this condition know what it’s like to feel winded just crossing the room or climbing a single flight of stairs. The underlying issue is high blood pressure in the arteries carrying blood from the heart to the lungs. Over time, this strain can wear down the heart and make regular activities a real challenge. Pulmonary hypertension isn’t rare anymore. More often, folks are showing up at clinics with symptoms their families never imagined—shortness of breath, chest pain, and swelling in the legs all point to something deeper going on.
Riociguat landed on the scene as a prescription medicine for adults with specific types of pulmonary hypertension: chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Unlike older drugs, Riociguat targets a unique pathway in the lungs known as the nitric oxide pathway, which relaxes blood vessels and lets blood flow where it should. By acting as a stimulator of an enzyme called soluble guanylate cyclase, Riociguat helps lower the pressure inside the lungs.
The FDA gave Riociguat approval after studies showed that patients covered more ground on foot—measured simply with a six-minute walk test—compared to those taking placebo. Quality of life matters just as much as lab numbers, and for many, Riociguat means fewer hospital stays and more time doing what they love.
No pill comes free of trade-offs. Riociguat can drop blood pressure lower than some people can handle, creating lightheadedness or fainting. People have to watch out for bleeding problems and shouldn’t take nitrates or drugs for erectile dysfunction alongside Riociguat. Doctors regularly check blood pressure and kidney health throughout treatment, and women of childbearing age must use strict birth control since Riociguat can cause birth defects.
Many of my patients appreciate the regular follow-ups that come with this medication. It’s not just about adjusting doses. Folks gain comfort from knowing someone’s checking up on their journey. They often tell me the difference between a good day and a hard day rides on whether they can trust their treatment and their team.
There’s still ground to cover. Many people don’t get diagnosed until the disease is pretty advanced. Riociguat gives hope for those who can’t get surgery or didn’t benefit from it, especially in CTEPH. But insurance hurdles, side effects, and a lack of awareness keep too many people from reaching therapies that could improve their lives.
Teamwork between patients, pulmonologists, pharmacists, and family members helps smooth the ride. Info campaigns in primary care clinics and regular screening in high-risk groups could spare folks years of missed signs. Research continues on new combinations and on how Riociguat interacts with other treatments. Ultimately, people living with pulmonary hypertension show what it means to fight for every breath, and Riociguat stands as one tool making that fight a bit more manageable.
Living with pulmonary hypertension rattles the body from the inside out. People with this problem feel tired all the time, climb a flight of stairs and feel like they’ve run a marathon. The blood vessels going from the heart to the lungs start to close up, and the heart’s left straining to push blood through. Riociguat comes in as a small tablet, but inside it’s doing much more than what sits on the surface.
Understanding riociguat’s value means looking at how blood vessels relax. Most older drugs just wrangle the symptoms, but riociguat pushes deeper. It hits a chemical path in the body called the nitric oxide–soluble guanylate cyclase (sGC) pathway. Normally, nitric oxide helps widen blood vessels, making it easier for the heart to do its job. Pulmonary hypertension mucks up that path, shutting off the natural signals. Riociguat actually stimulates the enzyme sGC—giving it a push, even when nitric oxide levels tank. Blood vessels finally get the message to open wider, and people start catching their breath again.
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) don't respond as easily to routine treatments. Riociguat stands out here because it works no matter if there's enough nitric oxide. Clinical trials, some big, some lasting nearly a year, back this up. One study saw patients cover longer distances during a simple walking test, and more said they could carry out daily tasks. For families and patients, those numbers aren’t just statistics—they show up as afternoons that don’t end on the couch, as better weekends spent with grandkids.
Doctors don’t hand out riociguat without thinking it through. I've seen dozens of patients enter with oxygen tanks and leave, a few months later, with less of that constant dragging fatigue. Blood pressure can drop if the medicine works too fast, and some folks feel dizzy at first. The medication also demands careful hand-holding: people using drugs for erectile dysfunction or certain nitrates must stay away because the mix can plummet blood pressure to dangerous lows. Regular blood checks matter—swelling or chest pain should get attention right away.
Insurance battles come into play. Treatment can cost thousands each month, so teams pull together letters and medical notes. Experience proves it helps to keep detailed records, show progress, and appeal again if the first try stalls. For families with limited means, hospital social workers take up the fight, tapping into manufacturer programs or nonprofit grants.
Pulmonary hypertension rarely gets cured, but with riociguat, some momentum returns. More work still lies ahead. Not all patients respond, and lung damage sometimes stays. Big city clinics have the resources to track side effects and boost lung rehab, but smaller hospitals stretch just to keep up. Expanding training for staff out in smaller communities could get more patients stable, so fewer folks need to travel just to breathe a little easier.
Science put a new tool in the box with riociguat, but real help requires a team. Every time I see someone go further down the sidewalk or pick up a grandchild again, it becomes clear why drugs like this matter. It’s about turning small improvements into bigger changes across a whole life.
Riociguat belongs to a family of drugs targeting pulmonary hypertension, a tough condition where blood vessels in the lungs get too narrow. It stood out in the past decade as a new hope for many dealing with shortness of breath and fatigue. Approved by the FDA in 2013, I’ve seen patients finally walk a few blocks again after years of struggles. It’s not a miracle pill, though. Like any powerful medication, it brings a laundry list of side effects that deserve a closer look.
Dizziness shows up pretty often. Most folks I’ve talked with feel lightheaded, especially during those first couple of weeks. Some get a headache strong enough to reach for an extra pillow or ice pack. Nausea, too, likes to tag along with these pills, nudging folks to eat smaller meals or focus on lighter breakfasts.
Low blood pressure heads the list of real-world worries. Riociguat relaxes blood vessels so well that people sometimes find themselves sitting down to avoid blacking out. My advice for anyone taking it: stand up slowly and keep water handy. Nothing rattles a person quite like a sudden bout of wooziness in public.
Nosebleeds surprise more patients than you’d expect. The studies back it up: about one in every ten people get them, usually mild but occasionally messy. My patients often carry tissues in their jacket pockets and pay close attention during allergy season.
Upset stomach runs right behind the rest. This isn’t the type of queasiness shrugged off on a busy afternoon—it can turn a good meal into a chore. Some deal with diarrhea, while others complain about burping and stomach pain. In my own clinic, tweaking meal times and sticking with bland snacks helps some, but not all.
Swelling in the legs or ankles crops up sometimes, especially after a full day sitting at work. A few people even notice their fingers get puffy. Low blood pressure can also trigger a racing heart or an odd pounding in the chest. If anyone on the medication feels like something isn’t right, a quick check with their doctor helps keep things in check.
Less often, Riociguat nudges kidney function downward. I remember one patient whose bloodwork tipped us off before symptoms even started. It’s routine now to keep an eye on the numbers, especially if the person also takes other blood pressure drugs or has a history of kidney disease.
Bleeding ticks up in people taking blood thinners. Since pulmonary hypertension patients often need both types of medication, this combo demands a closer partnership between patient and doctor. It takes extra planning and regular bloodwork to keep bleeding risk from becoming a real danger.
Nobody likes reading through a long list of what might go wrong. From what I’ve seen, sharing small details with healthcare teams makes a big difference. Simple notes about dizziness or odd bruises help doctors fine-tune dosages or suggest practical ideas—like compression socks or switching meal times. Keeping communication open gives Riociguat a fighting chance to help without causing more harm than good.
Reliable information on every prescription adds peace of mind. The FDA and American Heart Association keep updated lists and safety advice. No one should feel stuck navigating this path alone, and every side effect—big or small—deserves a voice in the next appointment.
Doctors prescribe riociguat to help people diagnosed with certain forms of pulmonary hypertension, aiming to make it easier for them to breathe and exercise. At the same time, this isn’t a one-size-fits-all solution. Like many strong medications, riociguat comes with real risks for certain groups, and ignoring these warnings can lead to life-threatening issues. I’ve spent years watching friends and family weigh complicated health decisions, and it always reminds me how important it is to consider the whole picture— not just the benefits a pill might bring.
Riociguat poses a severe risk to anyone who is pregnant or planning to become pregnant. I’ve listened to OB-GYNs talk through medication options with women, and the risk of birth defects from riociguat is always near the top of the list of medicines to steer clear of. The FDA has issued a boxed warning on this subject. Even a single dose during pregnancy adds danger to the life and health of the developing baby. Girls and women who can get pregnant must use reliable contraception and enroll in a special program to monitor use. This isn’t just a precaution—it’s a necessity, and there’s no safe way around it.
No one should take riociguat together with other drugs called PDE5 inhibitors, like sildenafil (Viagra, Revatio) or tadalafil (Cialis, Adcirca). Medical studies report dangerous drops in blood pressure from these combinations. This isn’t a rare side effect; it happens often enough that doctors check medication lists repeatedly. Interruptions to blood flow leave people dizzy, faint, or at risk for worse problems like a stroke or heart attack. Some people get frustrated by strict rules on mixing medications, but these aren’t minor interactions—they’re serious, and anyone getting care for pulmonary hypertension deserves clear information, not guesswork.
Riociguat passes through the kidney and liver, meaning anyone struggling with serious kidney or liver disease faces a much greater risk of side effects. Complicating things, damage in these organs often builds up quietly, so some people might not realize their risk without regular checkups. I’ve seen older relatives who didn’t know their kidney function had slipped until a blood test revealed the truth. Taking riociguat without proper testing could turn a manageable problem into something much worse, and doctors weigh these risks every time they prescribe this drug.
Someone with chronically low blood pressure shouldn’t take riociguat, as it works in part by widening blood vessels, dropping blood pressure even further. Collapsing on the kitchen floor or fainting in the shower isn’t a minor complaint; it’s a daily risk for some, and adding riociguat can push people one step closer to a hospital trip. This is especially true for older adults, who already face more risk of falls and injuries.
Though rare, some people react badly to riociguat itself or its ingredients—leading to rashes, swelling, or trouble breathing. Any sign of an allergic reaction means stopping the medication and calling for help without delay.
Every prescription story comes back to personal context. A medication that’s a lifeline for one person can be a serious hazard for someone else. Patients deserve honest, clear talk from their doctor, pharmacist, and loved ones. Checking medical history, reviewing all medications, and regular monitoring protect people from hidden dangers. The right medication brings hope and comfort—but only with open eyes about what’s at stake if risks are ignored.
Riociguat helps people with certain types of pulmonary hypertension. It relaxes the blood vessels in the lungs, making it easier for the heart to pump blood. For anyone dealing with breathing problems from this disease, the relief can feel real. Still, this medication carries serious risks that call for daily attention. Missing details or skipping warnings can cost someone their health.
Pregnant people should avoid riociguat at all costs. This drug can harm an unborn baby and may even cause birth defects. Doctors run regular pregnancy tests for people who could get pregnant, and effective contraception stands as a non-negotiable part of the plan. The pill doesn’t play well with some other medicines, especially nitrates or PDE5 inhibitors, like sildenafil or tadalafil, that treat erectile dysfunction or heart-related issues. Mixing those up can drop blood pressure so low that some people faint or worse.
Sharing your health history with your doctor goes beyond the obvious stuff. It helps to talk honestly about kidney and liver health, since these organs handle and process the drug. If someone has problems with either, riociguat can build up where it shouldn’t, raising the risk of side effects. People with low blood pressure, or those who faint easily, must mention these facts. Sometimes side effects sneak up and hit quietly. Better to head off surprises before they start.
I’ve seen people take a list of medicines that would make anyone’s head spin. With riociguat, that list needs to shrink. No one should take it with nitrates or PDE5 inhibitors. On top of that, certain antifungals, antibiotics, and HIV drugs can change the way riociguat works—either too much of it in the system or not enough. Always check with a doctor or pharmacist before adding anything new. Over-the-counter meds and herbal supplements bring their own risks. St. John’s Wort, for example, lowers riociguat levels and basically wastes the pills you swallow.
Feeling dizzy isn’t just an annoyance; dropping blood pressure means risk. For some, even standing up too fast can trigger a fall. Common side effects like headache, indigestion, nosebleeds, swelling, or nausea aren’t just small print on the label—they show that the body needs time to adjust or, sometimes, that a change in dose is needed. If vision changes, chest pain, rapid heartbeat, or trouble breathing show up, a trip to urgent care isn’t optional.
Smoking changes how the body handles riociguat, lowering its helpful effects. Smokers need to let their doctors know, and quitting helps both lungs and medication work better. Fast changes in weight or sudden leg swelling could signal heart issues—these must be taken seriously, not ignored until a yearly checkup. Daily routines matter. Sometimes meals and pill times get mixed up, or a double dose happens after a missed one. A simple calendar or alarm makes a huge difference for sticking with the right schedule.
Blood pressure checks don’t just belong in a clinic—many people keep small monitors at home. Catching problems early works better than chasing them once they start. Doctors ask for lab tests to check kidney and liver health through the course of treatment. Following up for those appointments protects both quality and length of life. A strong support team, open communication with healthcare workers, and staying informed protect against most surprises along the way.
| Names | |
| Preferred IUPAC name | methyl N-{(4,6-diamino-2-oxo-1,2-dihydro-1,3-benzodiazol-5-yl)oxy}-2-(pyrimidin-1-yl)acetate |
| Other names |
Adempas BAY 63-2521 |
| Pronunciation | /raɪˈoʊsɪˌɡwæt/ |
| Identifiers | |
| CAS Number | 625115-55-1 |
| 3D model (JSmol) | `3D_jMol("CN1C=NC2=C1C(=NC=N2)NCCCCC3=CC=NC=C3")` |
| Beilstein Reference | 6021488 |
| ChEBI | CHEBI:68511 |
| ChEMBL | CHEMBL1743086 |
| ChemSpider | 7643877 |
| DrugBank | DB08936 |
| ECHA InfoCard | 100.211.517 |
| EC Number | 681492-50-0 |
| Gmelin Reference | 104304 |
| KEGG | D09728 |
| MeSH | D061208 |
| PubChem CID | 24865624 |
| RTECS number | SQAJB5793F |
| UNII | Q9W0H00B0T |
| UN number | UN3241 |
| CompTox Dashboard (EPA) | DTXSID20865087 |
| Properties | |
| Chemical formula | C19H19FN8O2 |
| Molar mass | 391.715 g/mol |
| Appearance | White to yellowish-orange, non-hygroscopic, crystalline substance |
| Odor | Odorless |
| Density | 1.36 g/cm³ |
| Solubility in water | Sparingly soluble |
| log P | 1.89 |
| Vapor pressure | 9.53E-14 mm Hg |
| Acidity (pKa) | 4.0 |
| Basicity (pKb) | 4.26 |
| Magnetic susceptibility (χ) | -58.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.584 |
| Dipole moment | 3.1042 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -252.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5769 kJ/mol |
| Pharmacology | |
| ATC code | G04BX14 |
| Hazards | |
| Main hazards | May cause birth defects, hypotension, headache, dizziness, gastrointestinal symptoms, bleeding risk, contraindicated in pregnancy. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H332, H361fd |
| Precautionary statements | P201, P202, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| Flash point | 151 °C |
| Lethal dose or concentration | LD50 (oral, rat): >2000 mg/kg |
| LD50 (median dose) | > 82.4 mg/kg (rat, oral) |
| NIOSH | NLV7Y6SZ3C |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Riociguat: "Not established |
| REL (Recommended) | Pulmonary arterial hypertension |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
BAY 60-2770 Cinaciguat Imatinib Methylene blue |
